BR9810829A - Composto, processo para preparar o mesmo, composição, uso de um composto ou um sal farmaceuticamente aceitável do mesmo ou uma composição, e, processo de tratamento de uma condição - Google Patents
Composto, processo para preparar o mesmo, composição, uso de um composto ou um sal farmaceuticamente aceitável do mesmo ou uma composição, e, processo de tratamento de uma condiçãoInfo
- Publication number
- BR9810829A BR9810829A BR9810829-8A BR9810829A BR9810829A BR 9810829 A BR9810829 A BR 9810829A BR 9810829 A BR9810829 A BR 9810829A BR 9810829 A BR9810829 A BR 9810829A
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- compound
- group
- same
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- -1 C ~ 3 ~ -C ~ 6 ~ Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMPOSTO, PROCESSO PARA PREPARAR O MESMO, COMPOSIçãO, USO DE UM COMPOSTO OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO OU UMA COMPOSIçãO, E, PROCESSO DE TRATAMENTO DE UMA CONDIçãO" Compostos heterocíclicos de fórmula (I) em que R^ 1^ representa um átomo de hidrogênio ou um grupo -(CH~ 2~)~ m~-Y, em que m é um inteiro de 0 a 4 e Y representa um grupo alquila, haloalquila, alcoxi, alcoxicarbonila, cicloalquila C~ 3~-C~ 7~, um grupo norbornila ou fenilalquila, ou um grupo aromático, cujo grupo aromático Y pode ser opcionalmente substituído por um ou mais átomos de halogênio; R^ 2^ representa um grupo aromático, cujo grupo aromático pode ser opcionalmente substituído por um ou mais átomos de halogênio ou por grupos alquila, alcoxi, cicloalcoxi C~ 3~-C~ 6~, metilenodióxi, nitro, dialquilamino ou trifluorometila; e R^ 3^ representa um átomo de hidrogênio ou halogênio e um grupo alquila, e sais farmaceuticamente aceitáveis dos mesmos processos para preparar os mesmos. Os compostos são inibidores de fosfodiesterase.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES009701670A ES2137113B1 (es) | 1997-07-29 | 1997-07-29 | Nuevos derivados de triazolo-piridazinas heterociclicos. |
| PCT/EP1998/004340 WO1999006404A1 (en) | 1997-07-29 | 1998-07-13 | 1,2,4-triazolo[4,3-b]pyrido[3,2-d]pyridazine derivatives and pharmaceutical compositions containing them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR9810829A true BR9810829A (pt) | 2000-07-25 |
| BR9810829B1 BR9810829B1 (pt) | 2009-08-11 |
Family
ID=8300216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9810829-8A BR9810829B1 (pt) | 1997-07-29 | 1998-07-13 | composto heterocìclico, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica. |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US6407108B1 (pt) |
| EP (1) | EP1001955B1 (pt) |
| JP (1) | JP4320118B2 (pt) |
| KR (1) | KR20010022353A (pt) |
| CN (1) | CN1135231C (pt) |
| AR (1) | AR015927A1 (pt) |
| AT (1) | ATE207069T1 (pt) |
| AU (1) | AU737709B2 (pt) |
| BG (1) | BG64448B1 (pt) |
| BR (1) | BR9810829B1 (pt) |
| CA (1) | CA2298935A1 (pt) |
| CO (1) | CO4970780A1 (pt) |
| CZ (1) | CZ290208B6 (pt) |
| DE (1) | DE69802100T2 (pt) |
| DK (1) | DK1001955T3 (pt) |
| EE (1) | EE04313B1 (pt) |
| EG (1) | EG24041A (pt) |
| ES (2) | ES2137113B1 (pt) |
| HU (1) | HUP0004708A3 (pt) |
| ID (1) | ID24506A (pt) |
| IL (1) | IL134081A (pt) |
| MY (1) | MY118796A (pt) |
| NO (1) | NO315118B1 (pt) |
| NZ (1) | NZ502356A (pt) |
| PE (1) | PE111099A1 (pt) |
| PL (1) | PL191031B1 (pt) |
| PT (1) | PT1001955E (pt) |
| RU (1) | RU2202552C2 (pt) |
| SI (1) | SI1001955T1 (pt) |
| SK (1) | SK284046B6 (pt) |
| TR (1) | TR200000243T2 (pt) |
| TW (1) | TW542837B (pt) |
| UA (1) | UA60339C2 (pt) |
| WO (1) | WO1999006404A1 (pt) |
| ZA (1) | ZA986248B (pt) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2792938B1 (fr) * | 1999-04-28 | 2001-07-06 | Warner Lambert Co | NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV |
| AU777012B2 (en) | 1999-08-21 | 2004-09-30 | Takeda Gmbh | Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist |
| WO2002080974A1 (en) * | 2001-04-04 | 2002-10-17 | Sankyo Company, Limited | Novel medicinal use of cytokine production inhibitor |
| AU2002337105B2 (en) * | 2001-09-19 | 2008-03-20 | Takeda Gmbh | Combination of a NSAID and a PDE-4 inhibitor |
| FR2832711B1 (fr) * | 2001-11-26 | 2004-01-30 | Warner Lambert Co | Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation |
| US7608716B2 (en) | 2002-11-06 | 2009-10-27 | Aska Pharmaceutical Co., Ltd. | Pyrazolonaphthyridine derivative |
| ES2211344B1 (es) | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| JP2006522151A (ja) | 2003-04-01 | 2006-09-28 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 不妊症におけるホスホジエステラーゼ阻害剤 |
| US20050187278A1 (en) * | 2003-08-28 | 2005-08-25 | Pharmacia Corporation | Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors |
| RU2246496C1 (ru) * | 2003-09-12 | 2005-02-20 | Тец Виктор Вениаминович | Вещество с противовирусной и антибактериальной активностью на основе производных 2,8-дитиоксо-1h-пирано[2,3-d, 6,5-d`] дипиримидина и их 10-аза-аналогов |
| ES2251866B1 (es) | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| WO2006135627A2 (en) * | 2005-06-10 | 2006-12-21 | Merck & Co., Inc. | Inhibitors of akt activity |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| CN101268073B (zh) | 2005-09-15 | 2011-10-19 | Aska制药株式会社 | 杂环化合物、制备方法及其用途 |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2026813A2 (en) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| JP2010500365A (ja) | 2006-08-07 | 2010-01-07 | インサイト・コーポレイション | キナーゼ阻害剤としてのトリアゾロトリアジン |
| WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| CN103288833B (zh) | 2006-11-22 | 2018-01-12 | 因塞特控股公司 | 作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶 |
| WO2009089027A1 (en) * | 2008-01-09 | 2009-07-16 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Service, National Institutes Of Health | Phosphodiesterase inhibitors |
| DK2300455T3 (en) | 2008-05-21 | 2017-10-30 | Incyte Holdings Corp | SALTS OF 2-FLUORO-N-METHYL-4- [7- (QUINOLIN-6-YL-METHYL) - IMIDAZO [1,2-B] [1,2,4] TRIAZIN-2-YL] BENZAMIDE AND PROCEDURES WITH THE PREPARATION THEREOF |
| EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| EP2226323A1 (en) | 2009-02-27 | 2010-09-08 | Almirall, S.A. | New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives |
| PH12012501361A1 (en) | 2009-12-31 | 2012-10-22 | Centro Nac De Investigaciones Oncologicas Cnio | Tricyclic compounds for use as kinase inhibitors |
| BR112012019302B1 (pt) | 2010-02-03 | 2022-06-21 | Incyte Holdings Corporation | Imidazo[1,2-b] [1,2,4]triazinas como inibidores de c-met, composição que as compreende e métodos in vitro de inibir a atividade de c-met cinase, de inibir a via de sinalização da hgf/c-met cinase em uma célula e de inibir a atividade proliferativa de uma célula |
| EP2380890A1 (en) | 2010-04-23 | 2011-10-26 | Almirall, S.A. | New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors |
| EP2394998A1 (en) | 2010-05-31 | 2011-12-14 | Almirall, S.A. | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors |
| WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
| WO2013005057A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | New compounds |
| WO2013005041A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Tricyclic heterocyclic compounds as kinase inhibitors |
| WO2013004984A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Tricyclic compounds for use as kinase inhibitors |
| EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3122670A1 (de) | 1981-06-06 | 1982-12-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | "neue 1,4,9,10-tetrahydro-pyrazolo(4,3-e) pyrido(3,2-b)(1,4)diazepin-10-one, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von pharmazeutischen wirkstoffen" |
| FI81350C (fi) * | 1982-01-18 | 1990-10-10 | Lepetit Spa | Analogfoerfarande foer framstaellning av nya, farmakologiskt aktiva 6-substituerade s-triatsolo/3,4-a/ ftalazinderivat. |
| EP0217748B1 (en) * | 1985-09-30 | 1991-02-06 | Ciba-Geigy Ag | 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof |
| WO1991012251A1 (fr) * | 1990-02-19 | 1991-08-22 | Chugai Seiyaku Kabushiki Kaisha | Nouveau compose heterocyclique condense et agent anti-asthme prepare a partir de ce compose |
| KR100263494B1 (ko) * | 1991-10-09 | 2000-08-01 | 헤르빅 폰 모르체 | 피리도피리다지논 및 피리다진티온 화합물 |
| GB9514465D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| DE19510965A1 (de) * | 1995-03-24 | 1996-09-26 | Asta Medica Ag | Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung |
-
1997
- 1997-07-29 ES ES009701670A patent/ES2137113B1/es not_active Expired - Lifetime
-
1998
- 1998-07-13 ES ES98940218T patent/ES2162466T3/es not_active Expired - Lifetime
- 1998-07-13 ID IDW20000180A patent/ID24506A/id unknown
- 1998-07-13 AT AT98940218T patent/ATE207069T1/de not_active IP Right Cessation
- 1998-07-13 DK DK98940218T patent/DK1001955T3/da active
- 1998-07-13 CA CA002298935A patent/CA2298935A1/en not_active Abandoned
- 1998-07-13 UA UA2000010486A patent/UA60339C2/uk unknown
- 1998-07-13 KR KR1020007000932A patent/KR20010022353A/ko not_active Ceased
- 1998-07-13 SI SI9830042T patent/SI1001955T1/xx unknown
- 1998-07-13 BR BRPI9810829-8A patent/BR9810829B1/pt not_active IP Right Cessation
- 1998-07-13 CN CNB988081210A patent/CN1135231C/zh not_active Expired - Fee Related
- 1998-07-13 PL PL338214A patent/PL191031B1/pl not_active IP Right Cessation
- 1998-07-13 PT PT78400158T patent/PT1001955E/pt unknown
- 1998-07-13 SK SK86-2000A patent/SK284046B6/sk not_active IP Right Cessation
- 1998-07-13 IL IL13408198A patent/IL134081A/en active IP Right Grant
- 1998-07-13 JP JP2000505162A patent/JP4320118B2/ja not_active Expired - Fee Related
- 1998-07-13 EE EEP200000052A patent/EE04313B1/xx not_active IP Right Cessation
- 1998-07-13 NZ NZ502356A patent/NZ502356A/xx unknown
- 1998-07-13 CZ CZ2000333A patent/CZ290208B6/cs not_active IP Right Cessation
- 1998-07-13 WO PCT/EP1998/004340 patent/WO1999006404A1/en not_active Ceased
- 1998-07-13 HU HU0004708A patent/HUP0004708A3/hu unknown
- 1998-07-13 AU AU88612/98A patent/AU737709B2/en not_active Ceased
- 1998-07-13 DE DE69802100T patent/DE69802100T2/de not_active Expired - Fee Related
- 1998-07-13 RU RU2000104863/04A patent/RU2202552C2/ru not_active IP Right Cessation
- 1998-07-13 EP EP98940218A patent/EP1001955B1/en not_active Expired - Lifetime
- 1998-07-13 TR TR2000/00243T patent/TR200000243T2/xx unknown
- 1998-07-14 ZA ZA986248A patent/ZA986248B/xx unknown
- 1998-07-16 TW TW087111560A patent/TW542837B/zh not_active IP Right Cessation
- 1998-07-27 MY MYPI98003421A patent/MY118796A/en unknown
- 1998-07-28 CO CO98042905A patent/CO4970780A1/es unknown
- 1998-07-29 EG EG88998A patent/EG24041A/xx active
- 1998-07-29 AR ARP980103719A patent/AR015927A1/es active IP Right Grant
- 1998-07-30 PE PE1998000682A patent/PE111099A1/es not_active Application Discontinuation
-
2000
- 2000-01-26 NO NO20000394A patent/NO315118B1/no not_active IP Right Cessation
- 2000-01-27 BG BG104112A patent/BG64448B1/bg unknown
- 2000-01-28 US US09/496,019 patent/US6407108B1/en not_active Expired - Fee Related
-
2002
- 2002-01-08 US US10/038,777 patent/US20020183326A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9810829A (pt) | Composto, processo para preparar o mesmo, composição, uso de um composto ou um sal farmaceuticamente aceitável do mesmo ou uma composição, e, processo de tratamento de uma condição | |
| BR0014133A (pt) | Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica | |
| BR9911182A (pt) | Composto, uso do mesmo, processo para o tratamento de um mamìfero, incluindo homem, de condições suscetìveis de melhora por um agonista de beta-adrenorreceptor atìpico, composição farmacêutica, e, processo para a preparação de um composto. | |
| BR0015203A (pt) | Derivado de quinazolina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um composto, e, processo para a produção de um efeito antiangiogênico e/ou redutor de permeabilidade vascular em um animal de sangue quente | |
| BR9808552A (pt) | Composto tricìclico ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica | |
| EA200300354A1 (ru) | Хинолиноновые производные в качестве ингибиторов тирозинкиназы | |
| BR0014136A (pt) | Composto, uso do mesmo, métodos para a preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica | |
| CO5271675A1 (es) | Derivados de decahidro-isoquinolinas, proceso para su preparacion, composicion y compuestos farmaceuticos que los contienen | |
| ES2193362T3 (es) | Derivados de 2-pirimidinamina y su procedimiento de preparacion de los mismos. | |
| PT96897A (pt) | Processo para a preparacao de novos compostos aril-e heteroariletilenicos e de composicoes farmaceuticas que os contem | |
| BR9813989A (pt) | Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo para o tratamento de um paciente sofrendo de uma condição | |
| BR9913592A (pt) | Compostos, processo de preparação dos compostos, e, composições farmacêuticas | |
| BR9813390A (pt) | Composto, processo para a preparação do mesmo, e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, processo para efetuar a imunossupressão | |
| BR0214455A (pt) | Derivados benzotiazol | |
| BRPI0519058A2 (pt) | composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto | |
| BRPI9913542B8 (pt) | derivados de dihidrobenzodioxina carboxamida e dihidrobenzodioxina cetona como antagonistas do receptor 5-ht4 bem como composição farmacêutica, processo para a preparação dos referidos derivados e uso dos mesmos | |
| BR9307580A (pt) | Compostos processo para a preparação dos mesmos composições farmacêuticas uso de um composto e processo de tratamento de um mamífero que inclui o ser humano | |
| BR0313846A (pt) | Derivados de dioxano-2-alquilcarbamatos, sua preparação e sua aplicação em terapêutica | |
| BR0315056A (pt) | Compostos tendo tanto atividade agonista nicotìnica de alfa7 quanto atividade antagonista de 5ht3 para o tratamento de doenças do sistema nervoso central | |
| BR9811521A (pt) | Composição para tratar ou impedir a glomerulopatia | |
| BRPI0411285A (pt) | composto, processo para preparar um composto formulação farmacêutica, uso de um composto, e, método de prevenção ou tratamento de distúrbios | |
| BR9912575A (pt) | Processo para a preparação de um composto, e, composto. | |
| BR0209930A (pt) | Composto, composição farmacêutica, método para tratar doenças proliferativas, e, uso de um composto | |
| NO983493L (no) | Nye benzimidazol-, benzoksazol- og benzotiazolforbindelser, fremgangsmÕte ved fremstilling derav og farmas°ytiske sammensetninger inneholdende slike | |
| DE69307875D1 (de) | Acylaminoindolderivate als 5-ht1 agonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/08/2009, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE AS 13A, 14A, 15A, 16A E 17A ANUIDADES. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2342 DE 24-11-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |